>>Description of the research protocol "M14-011"

A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in
Phase III study| Status : Ongoing (but closed to recruitment)

Additional details

Indication (or studied pathology) : Cancer du sein Néo-adjuvant
Brugmann identifier : M14-011
EudraCT identifier : 2013-002377-21
ClinicalTrials.gov identifier : NCT02032277


Involved department : Hemato-oncology
Principal investigator : Efira
Sponsor : Abbvie
Contact : Clinical Research Unit

>This protocol was approved by the UCL St Luc ethics committee.